There is a need for new proteomics technologies to enable multiplexed assays of immune system response.
We aim to develop a novel technology for this application that is based on simultaneously measuring the binding of many customizable in silico-defined peptides. This technology could be applied to identify epitopes from pathogens, autoantigens, allergens or tumors for use in vaccine design and monitoring of immune responses.

Public Health Relevance

This proposal aims to establish a novel, high-throughput tool that can identify the particular components of a given pathogen, autoantigen, allergen or tumor that are best presented to the immune system by an individual. This tool could be used for vaccine design and monitoring of immune responses. More generally, the technology in this proposal would enable a novel approach for measuring inter-individual variation in the immune response.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43AI104140-01A1
Application #
8593060
Study Section
Special Emphasis Panel (ZRG1-IMM-G (10))
Program Officer
Prograis, Lawrence J
Project Start
2013-08-01
Project End
2014-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
1
Fiscal Year
2013
Total Cost
$223,808
Indirect Cost
Name
Prognosys Biosciences, Inc.
Department
Type
DUNS #
170943737
City
San Diego
State
CA
Country
United States
Zip Code
92121